Tumor Microenvironment Services
15 services found
Manufactured by:MedGenome Inc. based inCounty of New Castle, DELAWARE (USA)
Profiling the Tumor Microenvironment: Using a genomics based approach to analyze the tumor microenvironment can provide unique insights beyond IHC and FACS methods. OncoPeptTUME deeply interrogates RNA-Seq data sets to produce high resolution mapping of the tumor microenvironment using ...
Manufactured by:MedGenome Inc. based inCounty of New Castle, DELAWARE (USA)
Pathway enrichment analysis. Fusion and splicing event analysis with interactive genome browser to visualize results. Proprietary tumor microenvironment ...
Manufactured by:Veracyte based inMarseille Cedex 9, FRANCE
Leverage the widely used Nanostring platform to study gene expression in the tumor microenvironment, revealing biomarker signatures, mechanism of action, disease biology, and more. The most popular Nanostring service we offer is the nCounter® PanCancer IO 360™ Panel. This panel is designed to deliver immuno-oncology insights for translational research ...
Manufactured by:Elpiscience based inShanghai, CHINA
Elpiscience leverages our deep understanding of tumor biology and mechanisms of action to translate target biology for challenging pathways, develop biomarkers and strategically select indications and patients for clinical studies. We apply cutting-edge technologies including gene editing for target screening, single cell sequencing and advanced bioinformatics with over 1,000 ...
Manufactured by:BiomX based inNess Ziona, ISRAEL
Our colorectal cancer program utilizes engineered phage with various payloads (such as immunostimulatory payloads) that are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. The aim of payload delivery is to convert cold tumors to hot tumors with activated immune ...
Manufactured by:Veracyte based inMarseille Cedex 9, FRANCE
From our proprietary biomarkers, our innovated assays solutions, our unique data analysis platforms and our CDx development capabilities, we offer a comprehensive family of biomarker services that enhance your insight into the tumor microenvironment ...
Manufactured by:Immatics N.V. based inTuebingen, GERMANY
Immatics’ latest proprietary ACTengine® manufacturing processes are designed to generate cell product candidates within a short manufacturing window and deliver highly proliferative T cells, with the capability to infiltrate the patient’s tumor and function in a challenging solid tumor microenvironment. Immatics is actively ...
by:OracleBio based inGlasgow, UNITED KINGDOM
Adding value to Immuno-Oncology studies with Quantitative Digital Pathology. Quantitative Digital Pathology provides deep insights into the tumor microenvironment (TME), a knowledge which is crucial for understanding the mechanism of action of new oncology immunotherapies or for investigating new biomarkers. ...
by:Istari Oncology Inc. based inMorrisville, NORTH CAROLINA (USA)
The tumor environment contains all the ingredients needed to mount an anticancer immune response—tumor antigens, antigen presenting cells (APCs, including tumor-associated macrophages [TAMs] and dendritic cells), and T cells—but activation of the immune system to generate that antitumor response is complex and multifaceted. By ...
by:Flagship Biosciences Inc. based inBroomfield, COLORADO (USA)
For rapid and precise cancer care, pathologists and oncologists need dependable diagnostic testing to connect patients to individualized immuno-oncology therapies. Flagship’s TissueInsight® diagnostic service offers you access to robust, contextual data for advanced patient care. Our exclusive, targeted testing in our CAP/CLIA lab provides the most accurate and precise tissue scoring ...
Manufactured by:Kiadis Pharma NV based inAmsterdam, NETHERLANDS
Innovative antibody-based molecular concepts. New treatments for cancer that leverage our own immune system to attack and destroy cancer cells can provide long-term and durable therapeutic responses in patients suffering from life-threatening malignancies. These benefits for patients have been driven by recently developed therapeutic antibodies binding with high specificity to drug targets on ...
by:Champions Oncology, Inc. based inHackensack, NEW JERSEY (USA)
The Autologous TIL platform is an ex vivo 3D co-culture platform developed and optimized to interrogate the responses of your Immuno-Oncology drugs with a tumor-specific microenvironment in only 4 days using PDX-O (patient-derived xenograft organoids) collected with matched, autologous TIL ...
Manufactured by:Immatics N.V. based inTuebingen, GERMANY
ACTallo® is a process developed by Immatics for the manufacture of allogeneic, off-the-shelf, TCR-engineered cellular therapies derived from healthy donors’ gamma delta T ...
Manufactured by:XILIS, Inc. based inDurham, NORTH CAROLINA (USA)
Xilis’ rapid and scalable patient-derived MicroOrganoSphere (MOS) technology platform enhances precision medicine and pharmaceutical drug discovery and development. Compared to conventional patient-derived models, MOS provides faster, higher-throughput, and greater cost savings, as well as more predictive and accurate results. MOS can be used in large-scale pharmacogenomic studies that are ...
by:MtoZ Biolabs based in, MASSACHUSETTS (USA)
Proteolysis targeting chimera (PROTAC) drugs offer a novel approach to disease treatment by leveraging the body's innate protein degradation pathways. In contrast to traditional small-molecule inhibitors, PROTAC drugs promote the degradation of specific proteins rather than directly inhibiting their function, thus mitigating or eliminating their role in disease progression. ...